Senti Biosciences’ SENTI-202 Shows Promising Phase 1 Results

Senti Biosciences ( (SNTI) ) has issued an announcement.

Senti Biosciences reported encouraging initial results from a Phase 1 clinical trial of SENTI-202, an innovative CAR-NK cell therapy targeting hematologic malignancies like AML. Two out of three patients achieved complete remission at the initial dose, showing no detectable cancer cells, with the therapy being well-tolerated. The trial continues with dose escalation and further data expected in 2025, offering hope for patients with limited treatment options.

Find detailed analytics on SNTI stock on TipRanks’ Stock Analysis page.